Abstract:Nearly all children with nephrotic syndrome (NS) and podocyte gene mutations are resistant to steroid and immunosuppressants, except for two cases with PLCE1 mutations and focal segmental glomerulosclerosis (FSGS)/diffuse mesangial sclerosis (DMS) that responded to calcineurin inhibitor cyclosporine A (CsA) therapy. Cases with PLCE1 mutations and proliferation of the mesangium that showed a full and sustained response to the other calcineurin inhibitor tacrolimus (FK506) have not been reported. Two new compound heterozygous missense mutations (577G>A and 2770G>A) in PLCE1 were found in a 2-year-old girl with mild mesangial proliferation (Fig. 1). The PLCE1 gene encodes phospholipase C epsilon 1 (PLCε1). The compound heterozygous gene mutations 577G>A causes V193I, and 2770G>A causes the G924S change, had altered the function of PLCε1. The girl failed to respond to 4 weeks of prednisone, methylprednisolone pulse therapy and mycophenolate mofetil. However, she entered complete remission after 2 weeks of treatment with tacrolimus. She is free of proteinuria and her renal function is normal after more than 2 years of follow-up. The mechanism of action of calcineurin inhibitor on steroid resistant nephrolotic syndrome (SRNS) remains to be determined. Some studies showed that the beneficial effect of calcineurin inhibitor CsA on proteinuria results from thestabilization of the actin cytoskeleton in podocytes. CsA blocks the calcineurin-mediated dephosphorylation of synaptopodin thereby preserving the phosphorylation-dependent synaptopodin-14-3-3β interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin Lmediated degradation. Tacrolimus may have a similar effect to CsA as an anti-proteinuric agent. Though the mechanisms of these cases’ responses to therapy remain unknown, some scholars speculate that there might be a critical time window in disease during which treatment with CsA might overcome a putative developmental defect imposed by PLCE1 loss of function. These cases with PLCE1 mutations who respond to calcineurin inhibitors challenge the traditional view that podocyte disease does not require therapy with immunosuppressants, and imply that calcineurin inhibitors have antiproteinuric effects independent of their immunosuppressive effects. This is the first report of a case with PLCE1 novel mutations from China or East Asia, which enlarges the clinical spectrum of PLCE1 mutations. The full and sustained response to treatment suggests that tacrolimus had effects independent of its immunosuppressive actions.

Cardiac transplantation--the need for prospective, randomized, controlled investigations.

254C>G: a TRPC6 Promoter Variation Associated with Enhanced Transcription and Steroid-Resistant Nephrotic Syndrome in Chinese Children

A Multicenter Retrospective Study of Calcineurin Inhibitors in Nephrotic Syndrome Secondary to Podocyte Gene Variants

A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants (vol 103, pg 962, 2023)

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 ( RCAN1 ) Gene Confers Enhanced Calcineurin Activity and May Cause FSGS

Case Report: The Monogenic Familial Steroid-Resistant Nephrotic Syndrome Caused by a Novel Missense Mutation of NPHS2 Gene A593C in a Chinese Family

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

[A Child with Diffuse Mesangial Sclerosis Caused by a Missense Mutation of TRPC6 Gene].

Crumbs homolog 2 mutation in two siblings with steroid-resistant nephrotic syndrome: Two case reports

Genetic Variations of the NR3C1 Gene in Children with Sporadic Nephrotic Syndrome.

A Chinese Girl with Novel PLCE1 Mutations and Proliferation of the Mesangium Responded to Tacrolimus Therapy

Long-term Effects of Cyclosporine A in Children with Steroid-Resistant Idiopathic Nephrotic Syndrome and Outcomes of the Patients

Conversion from Calcineurin Inhibitors to Sirolimus in Chronic Allograft Nephropathy: a 4-Year Prospective Study

Adult-Onset Focal Segmental Glomerulosclerosis With Steroid-Dependent Nephrotic Syndrome Caused by a Novel TBC1D8B Variant: A Case Report and Literature Review

Case Report and Literature Review: A De Novo Pathogenic Missense Variant in ACTN4 Gene Caused Rapid Progression to End-Stage Renal Disease

The calcineurin regulatory subunit polymorphism and the treatment efficacy of tacrolimus for idiopathic membranous nephropathy

Novel mutation patterns in children with steroid-resistant nephrotic syndrome

Novel Pathogenic Mutation of P209L in TRPC6 Gene Causes Adult Focal Segmental Glomerulosclerosis